Advertisement

Gastric Neuroendocrine Neoplasia

  • Irvin M. Modlin
  • Mark Kidd
  • Maximillian V. Malfertheiner
  • Bjorn I. Gustafsson

Introduction

The enterochromaffin-like (ECL) cell is the best-characterized neuroendocrine cell in the gastric mucosa1 and constitutes one type of at least seven different neuroendocrine cell types (approximately 1%–2% of total mucosal cells) that comprise the fundic mucosa. The ECL cell, however, is the predominant endocrine cell population of the gastric fundus and accounts for approximately 35%–65% of the gastric endocrine cell mass 2 (Figure 7.1). The ECL cell is a pivotal regulator of acid secretion via a mechanism that involves its activation by circulating gastrin produced by antral G cells. Activation of the ECL CCK2R elicits the release of histamine which acts in a paracrine manner to initiate parietal cell secretion of protons into the gastric lumen (Figure 7.2). 3, 4Low acid states engendered by acid suppression or loss of parietal cell mass (atrophic or autoimmune gastritis) results in diminution of acid secretion, elevated luminal pH, activation of antral G cells,...

Keywords

Atrophic Gastritis Pernicious Anemia Gastrin Level Peptide Receptor Radionuclide Therapy Chronic Atrophic Gastritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Modlin IM, Tang LH. The gastric enterochromaffin-like cell: an enigmatic cellular link. Gastroenterology 1996;111(3):783–810.PubMedGoogle Scholar
  2. 2.
    Bordi C, D'Adda T, Azzoni C, Ferraro G. Classification of gastric endocrine cells at the light and electron microscopical levels. Microsc Res Tech 2000;48(5):258–71.PubMedGoogle Scholar
  3. 3.
    Prinz C, Zanner R, Gratzl M. Physiology of gastric enterochromaffin-like cells. Annu Rev Physiol 2003;65:371–82.PubMedGoogle Scholar
  4. 4.
    Lindstrom E, Chen D, Norlen P, Andersson K, Hakanson R. Control of gastric acid secretion: the gastrin-ECL cell-parietal cell axis. Comp Biochem Physiol A Mol Integr Physiol 2001;128(3):505–14.PubMedGoogle Scholar
  5. 5.
    Modlin IM, Lawton GP, Miu K, Kidd M, Luque EA, Sandor A, et al. Pathophysiology of the fundic enterochromaffin-like (ECL) cell and gastric carcinoid tumours. Ann R Coll Surg Engl 1996;78(2):133–8.PubMedGoogle Scholar
  6. 6.
    Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003; 12(2):153–72.PubMedGoogle Scholar
  7. 7.
    Smith AM, Watson SA, Caplin M, Clarke P, Griffin N, Varro A, et al. Gastric carcinoid expresses the gastrin autocrine pathway. Br J Surg 1998;85(9):1285–9.PubMedGoogle Scholar
  8. 8.
    Kitago M, Inada T, Igarashi S, Mizutani S, Ogata Y, Kubota T. Multiple gastric carcinoid tumors with type A gastritis concomitant with gastric cancer: a case report. Oncol Rep 2001;8(2):343–6.PubMedGoogle Scholar
  9. 9.
    Waldum HL, Haugen OA, Isaksen C, Mecsei R, Sandvik AK. Enterochromaffin-like tumour cells in the diffuse but not the intestinal type of gastric carcinomas. Scand J Gastroenterol Suppl 1991;180:165–9.Google Scholar
  10. 10.
    Modlin IM, Goldenring JR, Lawton GP, Hunt R. Aspects of the theoretical basis and clinical relevance of low acid states. Am J Gastroenterol 1994;89(3):308–18.PubMedGoogle Scholar
  11. 11.
    Godwin JD, 2nd. Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975;36(2):560–9.PubMedGoogle Scholar
  12. 12.
    Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934–59.PubMedGoogle Scholar
  13. 13.
    Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99(1):23–32.PubMedGoogle Scholar
  14. 14.
    Jansa SA, Weksler M. Phylogeny of muroid rodents: relationships within and among major lineages as determined by IRBP gene sequences. Mol Phylogenet Evol 2004;31(1):256–76.PubMedGoogle Scholar
  15. 15.
    Modlin IM, Lawton GP, Tang LH, Geibel J, Abraham R, Darr U. The mastomys gastric carci-noid: aspects of enterochromaffin-like cell function. Digestion 1994;55(Suppl 3):31–7.PubMedGoogle Scholar
  16. 16.
    Modlin IM, Esterline W, Kim H, Goldenring JR. Enterochromaffin-like cells and gastric argyrophil carcinoidosis. Acta Oncol 1991;30(4):493–8.PubMedGoogle Scholar
  17. 17.
    Schaffer K, McBride EW, Beinborn M, Kopin AS. Interspecies polymorphisms confer constitutive activity to the Mastomys cholecystokinin-B/gastrin receptor. J Biol Chem 1998;273(44):28779–84.PubMedGoogle Scholar
  18. 18.
    Bilchik AJ, Nilsson O, Modlin IM, Sussman J, Zucker KA, Adrian TE. H2-receptor blockade induces peptide YY and enteroglucagon-secreting gastric carcinoids in mastomys. Surgery 1989;106(6):1119–26; discussion 1126–7.PubMedGoogle Scholar
  19. 19.
    Kidd M, Hinoue T, Eick G, Lye KD, Mane SM, Wen Y, et al. Global expression analysis of ECL cells in Mastomys natalensis gastric mucosa identifies alterations in the AP-1 pathway induced by gastrin-mediated transformation. Physiol Genomics 2004;20(1):131–42.PubMedGoogle Scholar
  20. 20.
    Rozengurt E, Walsh JH. Gastrin, CCK, signaling, and cancer. Annu Rev Physiol 2001;63:49–76.PubMedGoogle Scholar
  21. 21.
    Chalmers CJ, Gilley R, March HN, Balmanno K, Cook SJ. The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcrip-tional output of AP-1. Cell Signal 2007;19(4):695–704.PubMedGoogle Scholar
  22. 22.
    Treinies I, Paterson HF, Hooper S, Wilson R, Marshall CJ. Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol 1999;19(1):321–9.PubMedGoogle Scholar
  23. 23.
    Kinoshita Y, Nakata H, Kishi K, Kawanami C, Sawada M, Chiba T. Comparison of the signal transduction pathways activated by gastrin in enterochromaffin-like and parietal cells. Gastroenterology 1998;115(1):93–100.PubMedGoogle Scholar
  24. 24.
    Tang LH, Modlin IM, Lawton GP, Kidd M, Chinery R. The role of transforming growth factor alpha in the enterochromaffin-like cell tumor autonomy in an African rodent mastomys. Gastroenterology 1996;111(5):1212–23.PubMedGoogle Scholar
  25. 25.
    Kidd M, Modlin IM, Eick GN, Camp RL, Mane SM. Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. Am J Physiol Gastrointest Liver Physiol 2007;292(1):G191–200.PubMedGoogle Scholar
  26. 26.
    Syder AJ, Karam SM, Mills JC, Ippolito JE, Ansari HR, Farook V, et al. A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype. Proc Natl Acad Sci USA 2004;101(13):4471–6.PubMedGoogle Scholar
  27. 27.
    Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991;114(6):1285–94.PubMedGoogle Scholar
  28. 28.
    Brigstock DR. The CCN family: a new stimulus package. J Endocrinol 2003;178(2):169–75.PubMedGoogle Scholar
  29. 29.
    Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3(6):537–49.PubMedGoogle Scholar
  30. 30.
    Pan LH, Beppu T, Kurose A, Yamauchi K, Sugawara A, Suzuki M, et al. Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblast-oma. Neurol Res 2002;24(7):677–83.PubMedGoogle Scholar
  31. 31.
    Igarashi A, Hayashi N, Nashiro K, Takehara K. Differential expression of connective tissue growth factor gene in cutaneous fibrohistiocytic and vascular tumors. J Cutan Pathol 1998;25(3):143–8.PubMedGoogle Scholar
  32. 32.
    Shakunaga T, Ozaki T, Ohara N, Asaumi K, Doi T, Nishida K, et al. Expression of connective tissue growth factor in cartilaginous tumors. Cancer 2000;89(7):1466–73.PubMedGoogle Scholar
  33. 33.
    Kawase S, Ishikura H. Female-predominant occurrence of spontaneous gastric adenocarci-noma in cotton rats. Lab Anim Sci 1995;45(3):244–8.PubMedGoogle Scholar
  34. 34.
    Fossmark R, Martinsen TC, Bakkelund KE, Kawase S, Waldum HL. ECL-cell derived gastric cancer in male cotton rats dosed with the H2-blocker loxtidine. Cancer Res 2004;64(10):3687–93.PubMedGoogle Scholar
  35. 35.
    Waldum HL, Rorvik H, Falkmer S, Kawase S. Neuroendocrine (ECL cell) differentiation of spontaneous gastric carcinomas of cotton rats (Sigmodon hispidus). Lab Anim Sci 1999;49(3):241–7.PubMedGoogle Scholar
  36. 36.
    Martinsen TC, Kawase S, Hakanson R, Torp SH, Fossmark R, Qvigstad G, et al. Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis 2003;24(12):1887–96.PubMedGoogle Scholar
  37. 37.
    Fukushima Y, Matsui T, Saitoh T, Ichinose M, Tateishi K, Shindo T, et al. Unique roles of G protein-coupled histamine H2 and gastrin receptors in growth and differentiation of gastric mucosa. Eur J Pharmacol 2004;502(3):243–52.PubMedGoogle Scholar
  38. 38.
    Chen D, Zhao CM, Al-Haider W, Hakanson R, Rehfeld JF, Kopin AS. Differentiation of gastric ECL cells is altered in CCK(2) receptor-deficient mice. Gastroenterology 2002;123(2):577–85.PubMedGoogle Scholar
  39. 39.
    Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 2001;98(3):1118–23.PubMedGoogle Scholar
  40. 40.
    Debelenko LV, Emmert-Buck MR, Zhuang Z, Epshteyn E, Moskaluk CA, Jensen RT, et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology 1997;113(3):773–81.PubMedGoogle Scholar
  41. 41.
    Miyaoka Y, Kadowaki Y, Ishihara S, Ose T, Fukuhara H, Kazumori H, et al. Transgenic over-expression of Reg protein caused gastric cell proliferation and differentiation along parietal cell and chief cell lineages. Oncogene 2004;23(20):3572–9.PubMedGoogle Scholar
  42. 42.
    Fox JG, Rogers AB, Ihrig M, Taylor NS, Whary MT, Dockray G, et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res 2003;63(5):942–50.PubMedGoogle Scholar
  43. 43.
    Cao X, Tsukamoto T, Nozaki K, Tanaka H, Cao L, Toyoda T, et al. Severity of gastritis determines glandular stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. Cancer Sci 2007;98(4):478–83.PubMedGoogle Scholar
  44. 44.
    Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000;118(1):36–47.PubMedGoogle Scholar
  45. 45.
    Kagawa J, Honda S, Kodama M, Sato R, Murakami K, Fujioka T. Enterochromaffin-like cell tumor induced by Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2002;7(6):390–7.PubMedGoogle Scholar
  46. 46.
    Rudnicka W, Jarosinska A, Bak-Romaniszyn L, Moran A, Planeta-Malecka I, Wadstrom T, et al. Helicobacter pylori lipopolysaccharide in the IL-2 milieu activates lymphocytes from dyspeptic children. FEMS Immunol Med Microbiol 2003;36(3):141–5.PubMedGoogle Scholar
  47. 47.
    Kidd M, Tang LH, Schmid S, Lauffer J, Louw JA, Modlin IM. Helicobacter pylori lipopoly-saccharide alters ECL cell DNA synthesis via a CD14 receptor and polyamine pathway in mastomys. Digestion 2000;62(4):217–24.PubMedGoogle Scholar
  48. 48.
    Betton GR, Dormer CS, Wells T, Pert P, Price CA, Buckley P. Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole. Toxicol Pathol 1988;16(2):288–98.PubMedGoogle Scholar
  49. 49.
    Poynter D, Selway SA. Neuroendocrine cell hyperplasia and neuroendocrine carcinoma of the rodent fundic stomach. Mutat Res 1991;248(2):303–19.PubMedGoogle Scholar
  50. 50.
    Goldenring JR, Ray GS, Coffey RJ, Meunier PC, Haley PJ, Barnes TB, et al. Reversible drug-induced oxyntic atrophy in rats. Gastroenterology 2000;118(6):1080–93.PubMedGoogle Scholar
  51. 51.
    Bakke I, Hammer TA, Sandvik AK, Waldum HL. PPAR alpha stimulates the rat gastrin-producing cell. Mol Cell Endocrinol 2002;195(1–2):89–97.PubMedGoogle Scholar
  52. 52.
    McDonald R. A study of 356 carcinoids of the gastrointestinal tract. Am J Med 1956;21:867–72.Google Scholar
  53. 53.
    Modlin IM, Kidd M, Latich I. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128(6):1717–51.PubMedGoogle Scholar
  54. 54.
    Borch K. Atrophic gastritis and gastric carcinoid tumours. Ann Med 1989;21(4):291–7.PubMedGoogle Scholar
  55. 55.
    Cadiot G, Laurent-Puig P, Thuille B, Lehy T, Mignon M, Olschwang S. Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology 1993;105(2):579–82.PubMedGoogle Scholar
  56. 56.
    Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005;19(12):1610–2.PubMedGoogle Scholar
  57. 57.
    Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104(4):994–1006.PubMedGoogle Scholar
  58. 58.
    Gough DB, Thompson GB, Crotty TB, Donohue JH, Kvols LK, Carney JA, et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994;18(4):473–9; discussion 479–80.PubMedGoogle Scholar
  59. 59.
    Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 2006;84(3):158–64.PubMedGoogle Scholar
  60. 60.
    Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995;90(3):338–52.PubMedGoogle Scholar
  61. 61.
    Creutzfeldt W, Stockmann F. Carcinoids and carcinoid syndrome. Am J Med 1987;82(5B): 4–16.PubMedGoogle Scholar
  62. 62.
    McCloy RF, Arnold R, Bardhan KD, Cattan D, Klinkenberg-Knol E, Maton PN, et al. Pathophysiological effects of long-term acid suppression in man. Dig Dis Sci 1995;40(2 Suppl):96S–120S.PubMedGoogle Scholar
  63. 63.
    Torbenson M, Abraham SC, Boitnott J, Yardley JH, Wu TT. Autoimmune gastritis: distinct histological and immunohistochemical findings before complete loss of oxyntic glands. Mod Pathol 2002;15(2):102–9.PubMedGoogle Scholar
  64. 64.
    Hodges JR, Isaacson P, Wright R. Diffuse enterochromaffin-like (ECL) cell hyperplasia and multiple gastric carcinoids: a complication of pernicious anaemia. Gut 1981;22(3):237–41.PubMedGoogle Scholar
  65. 65.
    Solcia E, Fiocca R, Villani L, Luinetti O, Capella C. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogene-sis. Am J Surg Pathol 1995;19(Suppl 1):S1–7.PubMedGoogle Scholar
  66. 66.
    Rashid N, Modlin I, Tang L, Wright N. The proliferative status of enterochromaffin-like (ECL) cells in the gastric mucosa. The plot thickens. Gastroenterology 1997;112:A644.Google Scholar
  67. 67.
    Annibale B, Azzoni C, Corleto VD, di Giulio E, Caruana P, D'Ambra G, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol 2001;13(12):1449–56.PubMedGoogle Scholar
  68. 68.
    Bordi C. Gastric carcinoids. Ital J Gastroenterol Hepatol 1999;31(Suppl 2):S94–7.PubMedGoogle Scholar
  69. 69.
    Waldum HL, Brenna E. Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 2000;14(1):15–22.PubMedGoogle Scholar
  70. 70.
    Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14(6):651–68.PubMedGoogle Scholar
  71. 71.
    Solcia E, Fiocca R, Rindi G, Villani L, Cornaggia M, Capella C. The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 1993;22(4):795–821.PubMedGoogle Scholar
  72. 72.
    Carcinoid tumors. International symposium on pathology, epidemiology, clinical aspects and therapy. January 13–16, 1994, Munich, Germany. Proceedings. Digestion 1994;55(Suppl 3):1–113.Google Scholar
  73. 73.
    Lehy T, Mignon M, Cadiot G, Elouaer-Blanc L, Ruszniewski P, Lewin MJ, et al. Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment. Gastroenterology 1989;96(4):1029–40.PubMedGoogle Scholar
  74. 74.
    Kumashiro R, Naitoh H, Teshima K, Sakai T, Inutsuka S. Minute gastric carcinoid tumor with regional lymph node metastasis. Int Surg 1989;74(3):198–200.PubMedGoogle Scholar
  75. 75.
    Moesta KT, Schlag P. Proposal for a new carcinoid tumour staging system based on tumour tissue infiltration and primary metastasis; a prospective multicentre carcinoid tumour evaluation study. West German Surgical Oncologists' Group. Eur J Surg Oncol 1990;16(4):280–8.PubMedGoogle Scholar
  76. 76.
    Solica E, Kloppel G, Sobin L. Histological typing of the endocrine tumors. Berlin: Springer Verlag; 2000.Google Scholar
  77. 77.
    Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004;1014:13–27.PubMedGoogle Scholar
  78. 78.
    Calender A. Molecular genetics of neuroendocrine tumors. Digestion 2000;62(Suppl 1):3–18.PubMedGoogle Scholar
  79. 79.
    Debelenko LV, Zhuang Z, Emmert-Buck MR, Chandrasekharappa SC, Manickam P, Guru SC, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associ-ated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 1997;57(11): 2238–43.PubMedGoogle Scholar
  80. 80.
    D'Adda T, Keller G, Bordi C, Hofler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 1999;79(6):671–7.PubMedGoogle Scholar
  81. 81.
    Kidd M, Shapiro MD, Mane SM, Modlin IM. The utility of AP-1 gene analysis of human gastric ecl cell carcinoid tumors to define gastrin-autonomy and determine tumor types. Gastroenterology 2004;126(Suppl 2):T1184.Google Scholar
  82. 82.
    Kidd M, Modlin IM, Mane SM, Camp RL, Eick GN, Latich I, et al. Utility of molecular genetic signatures in the delineation of gastric neoplasia. Cancer 2006;106(7):1480–8.PubMedGoogle Scholar
  83. 83.
    Kidd M, Modlin IM, Mane SM, Camp RL, Shapiro MD. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Ann Surg 2006; 243(2):273–80.PubMedGoogle Scholar
  84. 84.
    Modlin IM, Latich I, Zikusoka M, Kidd M, Eick G, Chan AK. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol 2006;40(7):572–82.PubMedGoogle Scholar
  85. 85.
    Krenning EP, Kooij PP, Pauwels S, Breeman WA, Postema PT, De Herder WW, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996;57(Suppl 1):57–61.PubMedGoogle Scholar
  86. 86.
    Granberg D, Wilander E, Stridsberg M, Granerus G, Skogseid B, Oberg K. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 1998;43(2):223–8.PubMedGoogle Scholar
  87. 87.
    Sanduleanu S, De Bruine A, Stridsberg M, Jonkers D, Biemond I, Hameeteman W, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001;31(9):802–11.PubMedGoogle Scholar
  88. 88.
    Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004;150(3):299–303.PubMedGoogle Scholar
  89. 89.
    Ruszniewski P, Ramdani A, Cadiot G, Lehy T, Mignon M, Bonfils S. Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome. Eur J Clin Invest 1993;23(5):296–301.PubMedGoogle Scholar
  90. 90.
    Annibale B, Delle Fave G, Azzoni C, Corleto V, Camboni G, D'Ambra G, et al. Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G-cell hyperfunction. Aliment Pharmacol Ther 1994;8(1):95–104.PubMedGoogle Scholar
  91. 91.
    Fykse V, Sandvik AK, Waldum HL. One-year follow-up study of patients with enterochro-maffin-like cell carcinoids after treatment with octreotide long-acting release. Scand J Gastroenterol 2005;40(11):1269–74.PubMedGoogle Scholar
  92. 92.
    Modlin IM, Latich I, Kidd M, Zikusoka M, Eick G. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006;4(5):526–47.PubMedGoogle Scholar
  93. 93.
    Jensen R. Carcinoid tumors and the carcinoid syndrome. In: Vincent T. DeVita, Jr., Samuel Hellman, and Steven A. Rosenberg, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven Publishers; 1997:1704–23.Google Scholar
  94. 94.
    Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplas-tic variants of these neoplasms. Cancer 1991;68(2):227–32.PubMedGoogle Scholar
  95. 95.
    Lachter J, Chemtob J. EUS may have limited impact on the endoscopic management of gastric carcinoids. Int J Gastrointest Cancer 2002;31(1–3):181–3.PubMedGoogle Scholar
  96. 96.
    Ichikawa J, Tanabe S, Koizumi W, Kida Y, Imaizumi H, Kida M, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy 2003;35(3): 203–6.PubMedGoogle Scholar
  97. 97.
    Bordi C, Azzoni C, Ferraro G, Corleto VD, Gibril F, Delle Fave G, et al. Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome. Am J Clin Pathol 2000;114(3):419–25.PubMedGoogle Scholar
  98. 98.
    Adda T, Pilato FP, Sivelli R, Azzoni C, Sianesi M, Bordi C. Gastric carcinoid tumor and its precursor lesions. Ultrastructural study of a case before and after antrectomy. Arch Pathol Lab Med 1994;118(6):658–63.PubMedGoogle Scholar
  99. 99.
    Kern SE, Yardley JH, Lazenby AJ, Boitnott JK, Yang VW, Bayless TM, et al. Reversal by antrectomy of endocrine cell hyperplasia in the gastric body in pernicious anemia: a morpho-metric study. Mod Pathol 1990;3(5):561–6.PubMedGoogle Scholar
  100. 100.
    Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005;242(1):64–73.PubMedGoogle Scholar
  101. 101.
    De Vries EG, Kema IP, Slooff MJ, Verschueren RC, Kleibeuker JH, Mulder NH, et al. Recent developments in diagnosis and treatment of metastatic carcinoid tumours. Scand J Gastroenterol Suppl 1993;200:87–93.PubMedGoogle Scholar
  102. 102.
    Davies MG, O'Dowd G, McEntee GP, Hennessy TP. Primary gastric carcinoids: a view on management. Br J Surg 1990;77(9):1013–4.PubMedGoogle Scholar
  103. 103.
    Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79(4):813–29.PubMedGoogle Scholar
  104. 104.
    Rappel S, Altendorf-Hofmann A, Stolte M. Prognosis of gastric carcinoid tumours. Digestion 1995;56(6):455–62.PubMedGoogle Scholar
  105. 105.
    Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998;243(6):477–88.PubMedGoogle Scholar
  106. 106.
    Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995;46:395–411.PubMedGoogle Scholar
  107. 107.
    Heidenhain R. Untersuchungen uber den Bau der Labdrusen. Arch Mikro Anat 1870;6:368–406.Google Scholar
  108. 108.
    Waldum HL, Aase S, Kvetnoi I, Brenna E, Sandvik AK, Syversen U, et al. Neuroendocrine differentiation in human gastric carcinoma. Cancer 1998;83(3):435–44.PubMedGoogle Scholar
  109. 109.
    Lamberts R, Creutzfeldt W, Stockmann F, Jacubaschke U, Maas S, Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988;39(2):126–35.PubMedGoogle Scholar
  110. 110.
    Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993;104(5):1356–70.PubMedGoogle Scholar
  111. 111.
    Solcia E, Rindi G, Havu N, Elm G. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol Suppl 1989;166:129–37; discussion 138–9.PubMedGoogle Scholar
  112. 112.
    Solcia E, Villani L, Luinetti O, Fiocca R. Proton pump inhibitors, enterochromaffin-like cell growth and Helicobacter pylori gastritis. Aliment Pharmacol Ther 1993;7(Suppl 1):25–8; discussion 29–31.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Irvin M. Modlin
    • 1
  • Mark Kidd
    • 1
  • Maximillian V. Malfertheiner
    • 2
  • Bjorn I. Gustafsson
    • 3
  1. 1.Yale University School of MedicineNew HavenUSA
  2. 2.GI Surgical Pathobiology Research GroupYale University School of MedicineNew HavenUSA
  3. 3.Department of SurgeryYale University School of MedicineNew HavenUSA

Personalised recommendations